Is combination therapy expanding clinical adoption across the ambrisentan tablet market?
Managing progressive pulmonary arterial hypertension (PAH) requires targeted oral therapies that lower pulmonary vascular resistance. Detailed analysis within the Ambrisentantable Market report demonstrates how ambrisentan—a selective endothelin type-A ($ET_A$) receptor antagonist—dilates pulmonary blood vessels to improve exercise capacity and delay clinical worsening in PAH...
0 Комментарии 0 Поделились 290 Просмотры 0 предпросмотр